Structural basis of a shared antibody response to SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Cited by
Items 101–200 of 597
Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions
Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H., & Sivaraman, J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.09.004 · Cited by 86
“33 neutralizes SARS pseudovirus SARS-2 RBD/RBM SARS RBD Likely compete with hACE-2 interface Do not compete with CR3022 Block hACE2–RBD binding Protect a hamster model 6XC2 6XC3 [27,32,34,93]”
Serological evidence of SARS‐CoV‐2 and co‐infections in stray cats in Spain
Villanueva‐Saz, S., Giner, J., Tobajas, A. P., Pérez, M. D., González‐Ramírez, A. M., Macías‐León, J., González, A. I., Verde, M., Yzuel, A., Hurtado‐Guerrero, R., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14062 · Cited by 88
He, B., Liu, S., Wang, Y., Xu, M., Cai, W., Liu, J., Bai, W., Ye, S., Ma, Y., Hu, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00610-7 · Cited by 87
“Highly potent SARS-CoV-2 mAbs show several distinct signatures, including: using a broad spectrum of variable (V) genes, low levels of somatic mutations, short CDRH3 loops, and minimal affinity maturation.(4,16) Similarly, we hypothesized that the B cells that produce the antibodies following SARS-CoV-2 infection may…”
BackgroundResultInfluentialDiscrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82
Kim, S. I., Noh, J., Kim, S., Choi, Y., Yoo, D. K., Lee, Y., Lee, H., Jung, J., Kang, C. K., Song, K.-H., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6990 · Cited by 81
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Shrestha, L. B., Tedla, N. T., & Bull, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752003 · Cited by 83
“Genetic characterization of SARS-CoV-2 nAbs described to date reveal enrichment of specific antibodyvariable genes, including VH3-53, VH3-66, VH1-2, VH1-69, VH158, and VH3-30 (16–17); VH3-53 and VH3-66 being the most commonly reported class of mAbs (17).”
BackgroundStructural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain
Smith, K. N., Clark, S. A., Shankar, S., Pan, J., Clark, L. E., Yang, P., Coscia, A., McKay, L. G. A., Varnum, H., Brusic, V., et al. (2022) · Science · doi:10.1126/science.abl6251 · Cited by 83
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
Reincke, S. M., Yuan, M., Kornau, H., Corman, V. M., van Hoof, S., Sánchez-Sendín, E., Ramberger, M., Yu, W., Hua, Y., Tien, H. J., et al. (2022) · Science · doi:10.1126/science.abm5835 · Cited by 80
“S6E), and might suggest a possible alternative binding mode or orientation compared to the two previously identified binding modes of wildtype VH3-53 antibodies that are usually sensitive either to K417N or to E484K ( 23 , 24 ).”
Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers
Rujas, E., Kucharska, I., Tan, Y. Z., Benlekbir, S., Cui, H., Zhao, T., Wasney, G. A., Budylowski, P., Guvenc, F., Newton, J. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23825-2 · Cited by 78
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.002 · Cited by 85
“High convergence in antibody responses against SARSCoV-2 is demonstrated by public clonotypes with conserved sequence characteristics and neutralization mechanisms (Nielsen et al., 2020; Robbiani et al., 2020; Yuan et al., 2020).”
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Zhao, F., Zai, X., Zhang, Z., Xu, J., & Chen, W. (2022) · npj Vaccines · doi:10.1038/s41541-022-00597-4 · Cited by 88
Yan, R., Wang, R., Ju, B., Yu, J., Zhang, Y., Liu, N., Wang, J., Zhang, Q., Chen, P., Zhou, B., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00487-9 · Cited by 76
“Up to now, numerous nAbs against the S protein of SARS-CoV-2 have been reported (17-23).”
BackgroundWu, N. C., Yuan, M., Bangaru, S., Huang, D., Zhu, X., Lee, C.-C. D., Turner, H. L., Peng, L., Yang, L., Burton, D. R., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009089 · Cited by 74
“have a KD of 17 nM and 14 nM to SARS-CoV-2 RBD, respectively, neutralize SARS-CoV-2 at an IC50 of ~20 ng/ml [3,37].”
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00139 · Cited by 63
Diversity in immunogenomics: the value and the challenge
Peng, K., Safonova, Y., Shugay, M., Popejoy, A. B., Rodriguez, O. L., Breden, F. J., Brodin, P., Burkhardt, A. M., Bustamante, C. D., Cao‐Lormeau, V., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01169-5 · Cited by 77
Cerutti, G., Guo, Y., Wang, P., Nair, M. S., Wang, M., Huang, Y., Yu, J., Liu, L., Katsamba, P. S., Bahna, F., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109928 · Cited by 72
“…neutralizing antibodies to recognize RBD at multiple distinct sites, and have further revealed multi-donor RBD-directed antibody classes that appear to be elicited with high frequency in the human population (Barnes et al., 2020b; Robbiani et al., 2020; Wu et al., 2020a; Yuan et al., 2020).”
InfluentialPlanchais, C., Fernández, I., Bruel, T., de Melo, G. D., Prot, M., Beretta, M., Guardado‐Calvo, P., Dufloo, J., Molinos-Albert, L. M., Backović, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220638 · Cited by 78
A rapid cell-free expression and screening platform for antibody discovery
Hunt, A. C., Vögeli, B., Hassan, A. O., Guerrero, L., Kightlinger, W., Yoesep, D. J., Krüger, A., DeWinter, M. A., Diamond, M., Karim, A. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38965-w · Cited by 86
Schepens, B., van Schie, L., Nerinckx, W., Roose, K., Breedam, W. V., Fijałkowska, D., Devos, S., Weyts, W., Cae, S. D., Vanmarcke, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi7826 · Cited by 72
SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies
Andreano, E., & Rappuoli, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01347-0 · Cited by 71
Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100527 · Cited by 84
“This is consistent with experimental evidence documenting Beta escape from class 1 and 2 antibodies 15,16 and Delta escape primarily from class 2 antibodies.”
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesPreprint
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.03.471045 · Cited by 69
Yi, C., Sun, X., Lin, Y., Gu, C., Ding, L., Lü, X., Yang, Z., Zhang, Y., Ma, L., Gu, W., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00985-w · Cited by 77
“We also observed that RBD-binding NAbs were strongly biased towards IGHV3-53/3-66, consistent with the findings of previous studies [4, 41, 42], which suggests that they play an important role in the humoral immune response to SARS-CoV-2 infection [43].”
ResultProtein engineering strategies for rational immunogen design
Caradonna, T. M., & Schmidt, A. G. (2021) · npj Vaccines · doi:10.1038/s41541-021-00417-1 · Cited by 75
Wang, Z., Zhou, P., Muecksch, F., Cho, A., Tanfous, T. B., Canis, M., Witte, L., Johnson, B., Raspe, R., Schmidt, F., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221006 · Cited by 63
Finkelstein, M. T., Mermelstein, A. G., Miller, E. P., Seth, P. C., Stancofski, E.-S. D., & Fera, D. (2021) · Viruses · doi:10.3390/v13010134 · Cited by 66
“3 from RBM Class I (PDB ID 6XC4 [59]), green for P2B-2F6 from”
BackgroundMannar, D., Saville, J. W., Sun, Z., Zhu, X. Q., Martí, M. M., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Sobolewski, M. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32262-8 · Cited by 68
Biswas, P., Hasan, M. M., Dey, D., Costa, A. C. D. S., Polash, S. A., Bibi, S., Ferdous, N., Kaium, M. A., Rahman, M. H., Jeet, F. K., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16096-3 · Cited by 64
“It contains two functional subunits: one is the S1 subunit (binds to the host cell receptor) towards the N-terminal, and another one is the S2 subunit (directly confers the fusion of the viral and cellular membrane) residing at the C-terminal (Walls et al. 2020; Zhou et al. 2020a; Yuan et al. 2020).”
BackgroundModular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
Rapp, M., Guo, Y., Reddem, E. R., Yu, J., Liu, L., Wang, P., Cerutti, G., Katsamba, P., Bimela, J. S., Bahna, F. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108950 · Cited by 64
Liu, H., Yuan, M., Huang, D., Bangaru, S., Zhao, F., Lee, C.-C. D., Peng, L., Barman, S., Zhu, X., Nemazee, D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.005 · Cited by 64
Verkhivker, G. M., & Paola, L. D. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00395 · Cited by 56
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Wheatley, A. K., Pymm, P., Esterbauer, R., Dietrich, M. H., Lee, W. S., Drew, D. R., Kelly, H. G., Chan, L., Mordant, F. L., Black, K. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109822 · Cited by 63
Dussupt, V., Sankhala, R. S., Mendez-Rivera, L., Townsley, S., Schmidt, F., Wieczorek, L., Lal, K. G., Donofrio, G. C., Tran, U., Jackson, N. D., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01068-z · Cited by 60
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Liu, C., Zhou, D., Nutalai, R., Duyvesteyn, H. M. E., Tuekprakhon, A., Ginn, H. M., Dejnirattisai, W., Supasa, P., Mentzer, A. J., Wang, B., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.11.013 · Cited by 66
“…the incubation temperature being below physiological, a substantial fraction of S was no longer trimeric, suggesting S destruction as a potential neutralization mecha- nism, as proposed for other non-ACE2-competing mAbs (STAR Methods) (Huo et al., 2020; Yuan et al., 2020b; Zhou et al., 2020).”
BackgroundCerutti, G., Rapp, M., Guo, Y., Bahna, F., Bimela, J., Reddem, E. R., Yu, J., Wang, P., Liu, L., Huang, Y., et al. (2021) · Structure · doi:10.1016/j.str.2021.05.014 · Cited by 62
“With respect to RBD-directed antibodies, however, while the most prevalent classes of multi-donor RBD-directed antibodies, originating from the VH3-53/66 and VH1-2 genes (Banach et al., 2021; Rapp et al., 2021; Yuan et al., 2020), are generally inhibited bymutations in RBD (K417N and N501Y for VH3-53/66 class antibodi…”
He, W., Musharrafieh, R. G., Song, G., Dueker, K., Tse, L. V., Martinez, D. R., Schäfer, A., Callaghan, S., Yong, P., Beutler, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01222-1 · Cited by 59
“A or class 1 nAb targeting the ACE2 binding site 9,59,65 ; (2) CC12.”
BackgroundDiscovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
Vanshylla, K., Fan, C., Wunsch, M., Poopalasingam, N., Meijers, M., Kreer, C., Kleipass, F., Ruchnewitz, D., Ercanoglu, M. S., Gruell, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.010 · Cited by 75
“Similar to other COVID-19 convalescent individuals (Cerutti et al., 2021; Chen et al., 2021a; Yuan et al., 2020), the SARS-CoV-2 spike-specific antibodies from elite neutralizers had a relative enrichment for IGHV3-30 (12.”
InfluentialOnodera, T., Kita, S., Adachi, Y., Moriyama, S., Sato, A., Nomura, T., Sakakibara, S., Inoue, T., Tadokoro, T., Anraku, Y., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.025 · Cited by 58
“Neutralizing RBS antibodies are frequently encoded by structurally related VH genes and share similar binding modes and footprints (Robbiani et al., 2020; Yuan et al., 2020b).”
InfluentialBanach, B. B., Cerutti, G., Fahad, A. S., Shen, C.-H., Oliveira De Souza, M., Katsamba, P. S., Tsybovsky, Y., Wang, P., Nair, M. S., Huang, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109771 · Cited by 60
“…L TMB substrate (00-4203-56, ThermoFisher Scientific, Waltham, MA) was used to detect antibody binding to antigen measuring absorbance at 405 nm. Pseudovirus SARS-CoV-2 viral neutralization assay SARS-CoV-2 pseudovirus neutralization assays were performed as previously described (Liu et al., 2020a).”
InfluentialDevelopment and application of therapeutic antibodies against COVID-19
Lin, N., Abagna, H. B., Jiang, Q., Liu, S., & Huang, J. H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59149 · Cited by 65
Advances in Neutralization Assays for SARS‐CoV‐2
Lu, Y., Jin, W., Li, Q., Hu, H., Lu, J., & Chen, Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13088 · Cited by 60
Modeling how antibody responses may determine the efficacy of COVID-19 vaccines
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00198-0 · Cited by 63
Fan, C., Cohen, A. A., Park, M., Hung, A. F.-H., Keeffe, J. R., Gnanapragasam, P. N. P., Lee, Y. E., Gao, H., Kakutani, L. M., Wu, Z., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.019 · Cited by 59
“Another concern is that the murine repertoire might lack V H and V L gene segments that provide humans with public responses against SARS-CoV-2 RBDs, 35 of which V H 3-53/V H 3-63, 36,37 V H 3-30, 17 and V H 1-2 38 antibodies have been described.”
Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 61
“A substantial component of the neutralizing response engages the receptor binding domain (RBD) ( 19-24 ) and does so by sterically blocking interactions with the viral receptor ACE2 ( 25-30 ).”
InfluentialFeng, Y., Yuan, M., Powers, J. M., Hu, M., Munt, J. E., Arunachalam, P. S., Leist, S. R., Bellusci, L., Kim, J., Sprouse, K. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7404 · Cited by 57
“3A. 25F9 targets one side of the RBD with some overlap with the conserved CR3022 site (Fig.”
BackgroundInfluentialRobinson, S. A., Raybould, M. I. J., Schneider, C., Wong, W. K., Marks, C., & Deane, C. M. (2021) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1009675 · Cited by 46
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
Ragonnet‐Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37826-w · Cited by 65
Structure and inhibition of SARS-CoV-2 spike refolding in membranes
Grunst, M. W., Qin, Z., Dodero‐Rojas, E., Ding, S., Prévost, J., Chen, Y., Hu, Y., Pazgier, M., Wu, S., Xie, X., et al. (2024) · Science · doi:10.1126/science.adn5658 · Cited by 62
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55
Rosenfeld, R., Noy-Porat, T., Mechaly, A., Makdasi, E., Levy, Y., Alcalay, R., Falach, R., Aftalion, M., Epstein, E., Gur, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21239-8 · Cited by 57
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
Gupta, D., Sharma, P., Singh, M., Kumar, M., Ethayathulla, A. S., & Kaur, P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04008-0 · Cited by 61
Pretrainable geometric graph neural network for antibody affinity maturation
Cai, H., Zhang, Z., Wang, M., Zhong, B., Li, Q., Zhong, Y., Wu, Y., Ying, T., & Tang, J. (2024) · Nature Communications · doi:10.1038/s41467-024-51563-8 · Cited by 81
“We chose PDB 6XC3 [30], in which chains H and L comprise antibody CR3022 446 and chain C is the SARS-CoV-2 RBD, as the starting complex.”
MethodJian, F., Wec, A. Z., Feng, L., Yu, Y., Wang, L., Wang, P., Yu, L., Wang, J., Hou, J., Berrueta, D. M., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-02030-7 · Cited by 58
“BD55-1205 has a relatively short complementarity-determining region (CDR) H3 of 11 amino acids (IMGT convention) compared with the average in the unselected repertoire 39,40 .”
Khatri, I., Staal, F. J. T., & van Dongen, J. J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.570018 · Cited by 57
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 58
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses
Dacon, C., Peng, L., Lin, T.-H., Tucker, C., Lee, C.-C. D., Cong, Y., Wang, L., Purser, L., Cooper, A. J. R., Williams, J. K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.010 · Cited by 56
Ding, H.-M., Yin, Y., Ni, S.-D., Sheng, Y.-J., & Ma, Y. (2021) · Chinese Physics Letters · doi:10.1088/0256-307x/38/1/018701 · Cited by 57
High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells
Chen, J., Chow, R. D.-W., Song, E., Mao, T., Israelow, B., Kamath, K., Bozekowski, J. D., Haynes, W. A., Filler, R. B., Menasché, B. L., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl5652 · Cited by 55
Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 55
“The prevalence of IGHV3-53 has been recognized in COVID-19 patients (Yan et al., 2021; Yuan et al., 2020).”
Protective neutralizing epitopes in SARS‐CoV‐2
Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 50
Ju, B., Zhang, Q., Wang, Z., Aw, Z. Q., Chen, P., Zhou, B., Wang, R., Ge, X., Lv, Q., Cheng, L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01449-6 · Cited by 50
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino-Urdaniz, I. M., Steiner, P. J., Kirby, M. B., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 49
On the road to ending the COVID-19 pandemic: Are we there yet?
Case, J. B., Winkler, E. S., Errico, J. M., & Diamond, M. (2021) · Virology · doi:10.1016/j.virol.2021.02.003 · Cited by 49
Pushparaj, P., Nicoletto, A., Sheward, D. J., Das, H., Dopico, X. C., Vidakovics, L. P., Hanke, L., Chernyshev, M., Narang, S., Kim, S., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.12.005 · Cited by 54
“Several mAbs used IGHV3-53 and had short HCDR3s, suggesting that they were of the previously described class 1 group of SARS-CoV-2-specific antibodies.(32,36) The IGHV3-53*01-using mAbs isolated here, including three clonally related mAbs, CAB-A17, CABA18, and CAB-A49, are separately described.”
BackgroundMosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals
Cohen, A. A., Keeffe, J. R., Schiepers, A., Dross, S., Greaney, A. J., Rorick, A. V., Gao, H., Gnanapragasam, P. N. P., Fan, C., West, A. P., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.052 · Cited by 55
Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics
Newby, M. L., Fogarty, C. A., Allen, J. D., Butler, J., Fadda, E., & Crispin, M. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167928 · Cited by 53
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00372 · Cited by 40
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
Yang, L., Beek, M. V., Wang, Z., Muecksch, F., Canis, M., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., & Chakraborty, A. K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112256 · Cited by 52
“Several human germline heavy chain genes exhibit high affinities for these epitopes.(15) Antibodies that develop from these germlines are highly enriched in response to both infection(16) and two doses of mRNA vaccination.”
Serapian, S. A., Marchetti, F., Triveri, A., Morra, G., Meli, M., Moroni, E., Sautto, G. A., Rasola, A., & Colombo, G. (2020) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.0c02341 · Cited by 48
“Importantly, for example, our calculation correctly identi fi es the binding region of the monoclonal Ab (mAb) CR3022 42 (see PDB entry 6W41), known to target a cryptic epitope that is exposed only upon signi fi cant structural rearrangement of the protein 12 (Figures 2 and 4).”
Production of trimeric SARS‐CoV‐2 spike protein by CHO cells for serological COVID‐19 testing
Johari, Y. B., Jaffe, S., Scarrott, J. M., Johnson, A. O., Mozzanino, T., Pohle, T. H., Maisuria, S., Bhayat‐Cammack, A., Lambiase, G., Brown, A. J., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27615 · Cited by 50
Antibody-guided structure-based vaccines
Kwong, P. D., DeKosky, B. J., & Ulmer, J. B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101428 · Cited by 45
Burnett, D. L., Jackson, K., Langley, D. B., Aggarwal, A., Stella, A. O., Johansen, M. D., Balachandran, H., Lenthall, H., Rouet, R., Walker, G. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.019 · Cited by 46
“IGHV3-53, which accounts for frequent germline-encoded antibodies against the hypervariable RBS region of CoV2 (Andreano and Rappuoli, 2021; Yuan et al., 2020), was strongly selected among the total set of sequencedRBD-binding B cells when compared to its frequency in the naive repertoire but was rarely used among the…”
Rossotti, M. A., van Faassen, H., Tran, A., Sheff, J. G., Sandhu, J. K., Duque, D., Hewitt, M., Wen, X., Bavananthasivam, J., Beitari, S., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03866-z · Cited by 48
Voss, W. N., Mallory, M. L., Byrne, P. O., Marchioni, J., Knudson, S. A., Powers, J. M., Leist, S. R., Dadonaite, B., Townsend, D. R., Kain, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101668 · Cited by 53
“…encoded by the IGHV2-26 gene segment, which is rarely utilized by human B cells to generate RBD-directed antibodies following a primary S exposure, 49 but its frequency increases substantially upon a hybrid immunological event as evidenced in our Ig-seq dataset and as supported by published…”
Inoue, T., Shinnakasu, R., Chie, K., Yamamoto, H. H., Sakakibara, S., Ono, C., Itoh, Y., Terooatea, T. W., Yamashita, K., Okamoto, T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221786 · Cited by 50
50 Years of structural immunology
Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 45
“The antibodies were also highly dominated by particular germline families (186, 187) that suggested that our humoral immune repertoire had off-the-shelf antibodies ready to spring into action.”
BackgroundWu, D., Kolesnikov, A. V., Yin, R. M., Guest, J. D., Gowthaman, R., Shmelev, A., Serdyuk, Y. V., Dianov, D. V., Efimov, G. A., Pierce, B. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27669-8 · Cited by 50
Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
Bouwman, K. M., Tomris, I., Turner, H. L., van der Woude, R., Shamorkina, T. M., Bosman, G. P., Rockx, B., Herfst, S., Snijder, J., Haagmans, B. L., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009282 · Cited by 40
Pan, Y., Du, J., Liu, J., Wu, H., Gui, F., Zhang, N., Deng, X., Song, G., Li, Y., Lu, J., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00295-w · Cited by 48
Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Dijokaite-Guraliuc, A., Das, R., Zhou, D., Ginn, H. M., Liu, C., Duyvesteyn, H. M. E., Huo, J., Nutalai, R., Supasa, P., Selvaraj, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112271 · Cited by 46
“Structure function analyses of panels of human monoclonal antibodies (mAbs) generated from convalescent SARS-CoV-2 cases have been performed by a number of laboratories, giving insight into the mechanisms of viral neutralization.(4,6,7,13,14) Most potently neutralizing antibodies bind on, or near, the ACE2 interaction…”
Brüssow, H. (2020) · Environmental Microbiology · doi:10.1111/1462-2920.15302 · Cited by 61
Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective
Huang, Y., Sun, H., Yu, H. J., Li, S., Zheng, Q., & Xia, N. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa028 · Cited by 45
Chen, F., Tzarum, N., Lin, X., Giang, E., Velázquez‐Moctezuma, R., Augestad, E. H., Nagy, K., He, L., Hernandez, M., Fouch, M. E., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.013 · Cited by 47
Kumar, V. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106980 · Cited by 44
“These IGHV3-53 Abs are very potent against SARS-CoV2 RBD and show minimum affinity maturation showing their promise as a vaccine design candidate [384].”
BackgroundYan, Q., He, P., Huang, X., Luo, K., Zhang, Y., Yi, H., Wang, Q., Li, F., Hou, R., Fan, X., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1925594 · Cited by 42
“in the germline sequence, further supporting that VH3-53 antibodies could develop rapidly and in high probability among many individuals [16].”
BackgroundInfluentialIncreased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine DosePreprint
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Tanfous, T. B., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.14.480394 · Cited by 41
Hanke, L., Sheward, D. J., Pankow, A., Vidakovics, L. P., Karl, V., Kim, C., Urgard, E., Smith, N. L., Astorga-Wells, J., Ekström, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm0220 · Cited by 38
“Nanobodies E2 and C7 are among the most potent monomeric neutralizing nanobodies isolated to date, consistent with targeting of a “class 2” epitope ( 27 ) overlapping the ACE2-binding site, which is highly represented among potently neutralizing antibodies isolated to date ( 45 , 46 ).”
Ford, C. T., Jacob Machado, D., & Janies, D. A. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.830202 · Cited by 52
Cho, H., Shim, S., Cho, W. W., Cho, S., Baek, H.-S., Lee, S.-M., & Shin, D. (2022) · ACS Sensors · doi:10.1021/acssensors.2c00317 · Cited by 40
Rouet, R., Henry, J. Y., Johansen, M. D., Sobti, M., Balachandran, H., Langley, D. B., Walker, G. J., Lenthall, H., Jackson, J., Ubiparipovic, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36295-5 · Cited by 42
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Tan, T. J. C., Mou, Z., Lei, R., Ouyang, W. O., Yuan, M., Song, G., Andrabi, R., Wilson, I. A., Kieffer, C., Dai, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37786-1 · Cited by 46
Ren, X., Sun, J., Kuang, W., Yu, F., Wang, B., Wang, Y., Deng, W., Zhao, X., Yang, S., Wáng, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51108-z · Cited by 42
Romagnoli, A., D’Agostino, M., Pavoni, E., Ardiccioni, C., Motta, S., Crippa, P., Biagetti, G., Notarstefano, V., Rexha, J., Perta, N., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101729 · Cited by 43
Wang, K., Cao, Y., Zhou, Y., Wu, J., Jia, Z., Hu, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21261735 · Cited by 45
Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J. C. C., Flyak, A. I., DeLaitsch, A. T., Huey-Tubman, K. E., Hou, S., et al. (2021) · doi:10.1101/2021.03.07.434227 · Cited by 39
“…have low levels of somatic hypermutation and nearly identical antibodies derived from specific rearranged antibody genes (e.g., VH3-53/VH3-63) (Barnes et al., 2020c; Robbiani et al., 2020; Yuan et al., 2020) are found in distinct convalescent or vaccinated individuals (Wang et al., 2021).”
BackgroundChangrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 41
“Our study also showed that anti-RBD mAbs are primarily class 2 mAbs, consistent with other reports (30, 37, 42, 50).”
ResultStructural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
Fu, D. B., Zhang, G., Wang, Y., Zhang, Z., Hu, H., Shěn, S., Wu, J., Li, B., Li, X., Fang, Y., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001209 · Cited by 41
Germline immunoglobulin genes: Disease susceptibility genes hidden in plain sight?
Collins, A. M., Yaari, G., Shepherd, A. J., Lees, W., & Watson, C. T. (2020) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2020.10.011 · Cited by 39
Metadata
- Authors
- Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., Rogers, T. F., Landais, E., Sok, D., Jardine, J. G., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Wilson, Ian A.
- ORCID
- Venue
- Science
- Published
- 2020-08-28
- Volume
- 369
- Issue
- 6507
- Pages
- 1119-1123
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402627
- OpenAlex
- W3041564586
- Cited by
- 589
- References
- 53
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 55 · 2023: 64 · 2022: 133 · 2021: 203 · 2020: 51
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Institutes of Health (K99 AI139445, UM1 AI44462)
- Bill and Melinda Gates Foundation (OPP1170236)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, neutralizing antibodies, receptor binding domain, spike protein, ACE2 binding site, co-crystal structure, germline antibodies, affinity maturation, vaccine design, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.